Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 10/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.33 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4124736 | 0.89 | CNR1 (0.34) | CNR1MAPTSMN1; SMN2TDP1 | |
| SCHEMBL2086773 | 0.88 | F10 (0.34) | CNR1MAPTSMN1; SMN2TDP1 | |
| SCHEMBL2085682 | 0.88 | CNR1 (0.33) | CNR1MAPTSMN1; SMN2TDP1LMNA | |
| SCHEMBL2085825 | 0.87 | MAPT (0.32) | CNR1MAPTSMN1; SMN2TDP1LMNA | |
| SCHEMBL4121879 | 0.85 | HTT (0.36) | CNR1MAPTSMN1; SMN2TDP1LMNA | |
| SCHEMBL4121872 | 0.84 | MAP4K4 (0.36) | CNR1MAPTSMN1; SMN2MAP4K4 | |
| SCHEMBL4112770 | 0.84 | NPC1 (0.33) | CNR1MAPTSMN1; SMN2TDP1LMNA | |
| SCHEMBL2084584 | 0.84 | MALT1 (0.32) | CNR1MAPTSMN1; SMN2 | |
| SCHEMBL2083247 | 0.83 | CNR1 (0.40) | CNR1 | |
| SCHEMBL4121225 | 0.81 | JAK2 (0.36) | MAPTSMN1; SMN2TDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188097-B2 | Pyrazolo[1,5-A]pyrimidine compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-05-29 | — | — | US | disclosed |
| US-20090069298-A1 | Pyrazolo[1,5-A]Pyrimidine Compounds | TANABE SEIYAKU CO., LTD. (JP) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069298-A1 | Pyrazolo[1,5-A]Pyrimidine Compounds | RECQL, QTRT1, DPYD | CNR1 285/4885MAPT 4568/4885SMN1; SMN2 3307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.